key: cord-1018653-zpvt61j7 authors: Kiani, Arda; Razavi, Fatemeh; Bandegani, Negar; Farahani, Mehrdad; Abedini, Atefeh title: Investigation of sarcoidosis patients during COVID-19 pandemic date: 2020-12-16 journal: Sarcoidosis Vasc Diffuse Lung Dis DOI: 10.36141/svdld.v37i4.9588 sha: 2820f34e4fac36e131c4d86e272f40a972fd9e02 doc_id: 1018653 cord_uid: zpvt61j7 nan 15.02.2020 until 10.04.2020 (300 patients with Covid-19), we have only encountered 10 cases of COVID-19 positive patients among all registered cases in the Sarcoidosis clinic of The National Research Institute of Tuberculosis and Lung Diseases (NRITLD) with approximately 1000 followed-up patients (Table 1 ). Our findings are in line with Conticini et al, cohort study in which 859 patients with different rheumatic diseases who were treated with disease-modifying antirheumatic drugs (DMARDs) were studied in Italy. Among those two patients were diagnosed with COViD-19 (4). It is worth to mention a patient of ours with sarcoidosis that has been under the treatment regimen, including methylprednisolone 5mg daily and 7.5 mg Methotrexate (MTX), for years. Her husband passed away due to COVID-19, that is while her test results were repeatedly negative for SARS-COV-2. There are several hypotheses in this regard. • Firstly, Angiotensin-converting enzyme-2 (ACE2) is a type of integral membrane glycoprotein. ACE2 that is expressed in the lungs and serves as the main entry point into cells for some coronaviruses (5) is involved in the progression of pulmonary sarcoidosis (6) . That is while the presence of the ACE2 enzyme protects lung cells from damage caused by the virus by increasing the level of the angiotensin-1-7 (7). • Secondly, sarcoidosis patients apply more selfprotection due to the history of chronic disease. It is possible that their extra precautions reduce the risk of being infected. • Moreover, their regimen consists of combinations of multiple medicaments including: methylprednisolone, Methotrexate (MTX), hydroxychloroquine, ect. Although it is not currently known how exactly these medicaments affect the COVID-19 infection, some of these medications suppress signs and symptoms of the disease; therefore, sarcoidosis patients taking them might be asymptomatic carriers of COVID-19 and pose a threat to their family and the society. • And finally, the sarcoidosis treatment regimen may have protective effects against COVID-19. In order to investigate all probable hypotheses in this regard, we are already conducting a study in which we follow up on our sarcoidosis patients regarding all their signs and symptoms that have developed recently. Herewith, we hope to find a new perspective on this disease. Coronavirus disease 2019 (COVID-2019). Accessed WHO) WHO. Coronavirus disease (COVID-19) outbreak. Accessed A prospective study of patients diagnosed with sarcoidosis: factors-environmental exposure, health assessment, and genetic outlooks. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Annals of the Rheumatic Diseases The novel coronavirus 2019 (2019-nCoV) uses the SARScoronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells Angiotensinconverting enzyme 2 (ACE2) haplotypes are associated with pulmonary disease phenotypes in sarcoidosis patients The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice